Establishment of a new human glioblastoma multiforme cell line (WJ1) and its partial characterization.
(1) A new human glioblastoma multiforme (GBM) cell line, WJ1, was established from the tissue derived from a 29-year-old patient diagnosed with a grade IV GBM. (2) The WJ1 cell line has been subcultured for more than 80 passages in standard culture media without feeder layer or collagen coatings. (3) GBM cells grow in vitro with distinct morphological appearance. Ultrastructural examination revealed large irregular nuclei and pseudo-inclusion bodies in nuclei. The cytoplasm contained numerous immature organelles and a few glia filaments. Growth kinetic studies demonstrated an approximate population doubling time of 60 h and a colony forming efficiency of 4.04%. The karyotype of the cells was hyperdiploid, with a large subpopulation of polyploid cells. Drug sensitivities of DDP, VP-16, tanshinone IIA of this cell line were assayed. They showed a dose- and time-dependent growth inhibition effect on the cells. (4) Orthotopic transplantation of GBM cells into athymic nude mice induced the formation of solid tumor masses about 6 weeks. The cells obtained from mouse tumor masses when cultivated in vitro had the same morphology and ultrastructure as those of the initial cultures. (5) This cell line may provide a useful model in vitro and in vivo in the cellular and molecular studies as well as in testing novel therapies for human glioblastoma multiforme.
Wang
Jing
J
Laboratory of Experimental Oncology, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, PR China.
Wang
Xiujie
X
Jiang
Shu
S
Lin
Ping
P
Zhang
Jie
J
Wu
Yaying
Y
Xiong
Zhujuan
Z
Ren
Jing Jing
JJ
Yang
Hongliang
H
D045784:Abietanes; D000328:Adult; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D001932:Brain Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000473:pathology*; D018929:Cell Culture Techniques; D002455:Cell Division; D045744:Cell Line, Tumor / Q000166:cytology*; D002945:Cisplatin / Q000494:pharmacology; D005047:Etoposide / Q000494:pharmacology; D005904:Glial Fibrillary Acidic Protein / Q000378:metabolism; D005909:Glioblastoma / Q000188:drug therapy / Q000235:genetics / Q000473:pathology*; D006801:Humans; D007381:Intermediate Filament Proteins / Q000378:metabolism; D007621:Karyotyping; D008297:Male; D051379:Mice; D008819:Mice, Nude; D009419:Nerve Tissue Proteins / Q000378:metabolism; D064231:Nestin; D010616:Phenanthrenes / Q000494:pharmacology; D023041:Xenograft Model Antitumor Assays
D045784:Abietanes; D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D005904:Glial Fibrillary Acidic Protein; D007381:Intermediate Filament Proteins; C577484:NES protein, human; D009419:Nerve Tissue Proteins; C577485:Nes protein, mouse; D064231:Nestin; D010616:Phenanthrenes; C021751:tanshinone; D005047:Etoposide; D002945:Cisplatin
Brain Pathol. 2002 Jan;12(1):117-32
11770894
Clin Cancer Res. 2003 Sep 15;9(11):4227-39
14519650
Anticancer Res. 1992 May-Jun;12(3):853-61
1320358
Clin Cancer Res. 2006 Sep 15;12(18):5288-97
17000661
Cancer Res. 2003 Sep 15;63(18):5821-8
14522905
Hematol Oncol Clin North Am. 2006 Dec;20(6):1193-214
17113459
J Neurooncol. 2007 Mar;82(1):11-21
16955220
J Neurosurg. 1998 Jan;88(1):1-10
9420066
J Neurosurg. 2007 Apr;106(4):652-9
17432718
Cancer Res. 2003 Mar 15;63(6):1311-6
12649192
Cell Mol Neurobiol. 2001 Aug;21(4):421-8
11775071
Genes Dev. 2001 Jun 1;15(11):1311-33
11390353
J Neurooncol. 1998 Nov;40(2):151-60
9892097
Nature. 2004 Nov 18;432(7015):396-401
15549107
Neuropathol Appl Neurobiol. 2000 Feb;26(1):22-30
10736064
Neurosurgery. 2007 Feb;60(2):360-70; discussion 370-1
17290188
Cancer Res. 2003 Jun 1;63(11):3001-4
12782610
Cancer Genet Cytogenet. 1998 May;103(1):46-51
9595044
In Vitro Cell Dev Biol Anim. 1998 Jun;34(6):439-42
9661044
Nat Rev Genet. 2001 Feb;2(2):120-9
11253051